Scot Niglio MD (@scotniglio) 's Twitter Profile
Scot Niglio MD

@scotniglio

Memorial Sloan Kettering genitourinary medical oncologist and cancer researcher. More importantly proud husband to a scientist 👩🏽‍🔬 and father.

ID: 52808843

calendar_today01-07-2009 18:35:45

611 Tweet

564 Takipçi

470 Takip Edilen

Selwyn M. Vickers (@drvickersmsk) 's Twitter Profile Photo

I am pleased to share that Memorial Sloan Kettering Cancer Center’s state-of-the-art cancer care  pavilion currently under construction will be named The Kenneth C. Griffin Pavilion at Memorial Sloan Kettering Cancer Center. We are deeply grateful to Ken for his extraordinary generosity and all he

I am pleased to share that <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a>’s state-of-the-art cancer care  pavilion currently under construction will be named The Kenneth C. Griffin Pavilion at Memorial Sloan Kettering Cancer Center. 

We are deeply grateful to Ken for his extraordinary generosity and all he
Scot Niglio MD (@scotniglio) 's Twitter Profile Photo

US FDA approves durvalumab in muscle invasive bladder cancer of off NIAGARA. Congratulations to Tom Powles and the investigators on the study. fda.gov/drugs/resource…

NYU Langone Health (@nyulangone) 's Twitter Profile Photo

We are thrilled to announce the appointment of Alec C. Kimmelman, MD, PhD, as the next Chief Executive Officer at NYU Langone Health and Dean of NYU Grossman School of Medicine effective September 1, 2025. Learn more: nyulangone.org/news/nyu-lango…

We are thrilled to announce the appointment of Alec C. Kimmelman, MD, PhD, as the next Chief Executive Officer at <a href="/nyulangone/">NYU Langone Health</a> and Dean of <a href="/nyugrossman/">NYU Grossman School of Medicine</a> effective September 1, 2025.

Learn more: nyulangone.org/news/nyu-lango…
Dr. Bishoy M. Faltas (@faltaslab) 's Twitter Profile Photo

🧩 ctDNA is a key piece of the puzzle in building an integrated precision oncology ecosystem at Weill Cornell Medicine Excited to share collaborative paper #2 this month. This time with the brilliant Alexandre Pellan Cheng & Dan Landau! rdcu.be/ehkUb Nature Methods Highlights: 🔬

🧩 ctDNA is a key piece of the puzzle in building an integrated precision oncology ecosystem at <a href="/WeillCornell/">Weill Cornell Medicine</a>

Excited to share collaborative paper #2 this month. This time with the brilliant <a href="/AlexandrePCheng/">Alexandre Pellan Cheng</a> &amp; <a href="/landau_lab/">Dan Landau</a>! rdcu.be/ehkUb <a href="/naturemethods/">Nature Methods</a> 

Highlights:
🔬
Ravi A Madan M.D. (@dr_ravimadan) 's Twitter Profile Photo

Updated data from #PSMA monitoring study in #BCR #ProstateCancer ASCO #ASCO25 Stop by & see our poster on Monday morning You can see what happens to this pt at 6 months 10+ LNs How would you have managed this case? Trial continues to accrue National Cancer Institute clinicaltrials.gov/study/NCT05588…

Updated data from #PSMA monitoring study in #BCR #ProstateCancer <a href="/ASCO/">ASCO</a> #ASCO25 

Stop by &amp; see our poster on Monday morning

You can see what happens to this pt at 6 months 10+ LNs

How would you have managed this case?

Trial continues to accrue <a href="/theNCI/">National Cancer Institute</a>

clinicaltrials.gov/study/NCT05588…
Brian Rini, MD (@brian_rini) 's Twitter Profile Photo

Matt Galsky discusses the ctDNA data from NIAGARA presented at #ASCO25. ctDNA positivity is distinct from path CR and ctDNA positive patients do poorly creators.spotify.com/pod/show/the-u…

Tom Powles (@tompowles1) 's Twitter Profile Photo

The most robust data post EVP in M1 bladder cancer by Michal Sternschuss MSKCC Carboplatin/gem was the commonest regimen #ASCO25 OncoAlert Results showed ⬆️ RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months previously?

The most robust data post EVP in M1 bladder cancer by Michal Sternschuss <a href="/mskcc/">MSKCC</a> Carboplatin/gem was the commonest regimen  #ASCO25 <a href="/OncoAlert/">OncoAlert</a> Results showed ⬆️ RRs than expected (50%) PFS =4.5 months &amp; OS =11 months are good. 1st line gem/carbo OS was ~10 months previously?
Goutham Sunny (@medoncodoc) 's Twitter Profile Photo

🔬 CONTACT-02 Phase 3 Trial in mCRPC 🔬 📍 Patients with metastatic castration-resistant prostate cancer + extrapelvic soft-tissue mets post-ARPI 💊 Cabozantinib + Atezolizumab vs ARPI switch ✅ PFS: 6.3 vs 4.2 mo (HR 0.65, P=0.0007) ❌ OS: No significant difference (14.8 vs

Andrea Necchi (@andreanecchi) 's Twitter Profile Photo

All that you can’t leave behind on MIBC is online Journal of Clinical Oncology ASCO @MattGalsky Ashish M. Kamat, MD, MBBS Leslie Ballas Muscle-Invasive Bladder Cancer: A Watershed Moment | Journal of Clinical Oncology ascopubs.org/doi/abs/10.120…

Ravi A Madan M.D. (@dr_ravimadan) 's Twitter Profile Photo

Important to distinguish #serosal findings on #PSMA 🩻vs. #parenchymal Serosal lesions are better seen on #PSMA vs CT/MRI in #ProstateCancer but likely have an indolent course even with no 🚫therapy (even on the liver!) Melissa Abel, MD et al.Nature Reviews Urology rdcu.be/eBwPs

Important to distinguish #serosal findings on #PSMA 🩻vs. #parenchymal

Serosal lesions are better seen on #PSMA vs CT/MRI in #ProstateCancer but likely have an indolent course even with no 🚫therapy (even on the liver!)

<a href="/melissaabel20/">Melissa Abel, MD</a> et al.<a href="/NatRevUrol/">Nature Reviews Urology</a>

rdcu.be/eBwPs
ABC News (@abc) 's Twitter Profile Photo

LATEST: Villanova University said news of a possible shooter at its law school was a "cruel hoax," after it issued an alert warning of an active shooter on its Pennsylvania campus. abcnews.link/9Mcyg0M